Voyager Technologies news

Strong Q2 growth metrics, record bookings, significant backlog, major defense contracts, strategic acquisitions, and optimistic 2026 revenue guidance of 66-84% growth. Stock surged 70% on these results.

The company completed a strategically important acquisition that creates a full-stack lunar mission capability and secured a major $298 million NASA contract, positioning it as a key player in the expanding space sector. However, this is tempered by financial concerns.

Presented as a hidden gem alternative to SpaceX IPO. $2B market cap company with 54% backlog growth to $275M, serving defense industry space market. Developing Starlab Space Stations as private alternative to ISS (decommissioning 2030). Speculative but intriguing long-term thesis.

Voyager secured a cost-effective Starship launch contract at $90M to deploy Starlab space station in 2029, achieving ISS-equivalent capabilities in a single launch versus decades and billions in traditional assembly costs. This represents exceptional value for the company's space station ambitions.

The company is successfully applying AI-driven digital engineering and automated manufacturing to compress design cycles and advance aerospace technologies from development to fielded capabilities, demonstrating innovation in the growing digital engineering sector.

Included in the curated list of four stocks expected to double; recommended by The Motley Fool, indicating positive outlook on the company's prospects.

While Astrobotic (its acquisition) won the largest contract, Voyager itself remains far from profitability with profits not expected until 2029, presenting significant investment risk despite contract success.

The acquisition of Astrobotic significantly expands Voyager's addressable market from space stations to lunar infrastructure. The deal appears strategically sound at potentially less than 1x sales, with access to $323 million in existing NASA contracts and potential recovery of a $610 million VIPER contract. This positions the company as a comprehensive lunar contractor.

Infrastructure leader developing Starlab commercial space station with raised guidance and rising analyst targets; Astrobotic acquisition positions it to benefit from sector re-rating and increased capital availability.

Cheapest valuation among alternatives at 16x price-to-sales with significant growth potential. Leading consortium to build replacement space station for ISS with growing momentum and no direct competition with SpaceX.

Record backlog of $275.3M, raised 2026 revenue guidance to $230-255M, selected for NASA's seventh Private Astronaut Mission, strong cash position of $429.4M, and Starlab already 130% subscribed on commercial payload capacity.

Despite current unprofitability with $116 million net loss in 2025, the company shows progress with $275.3 million backlog, raised 2026 revenue guidance to $230-255 million, has $641.4 million in liquidity, and secured NASA contracts. Strong backlog and improving trajectory support positive long-term potential despite near-term losses.

Partnered with Anduril and K2 Space to develop advanced solutions for the Space-Based Interceptor program, providing growth opportunities in the Golden Dome ecosystem.

Record Q4 net sales of $46.7M, full-year 2025 sales of $166.4M, raised 2026 revenue guidance to $225-255M, and record backlog of $265.6M. CEO highlighted transformational year with accelerating demand.

Gained 80% in its public debut, demonstrating strong investor appetite for space and defense firms amid increased military budgets.

Offers significantly larger habitat (400 cubic meters vs Vast's 45 cubic meters) capable of supporting 100% of ISS research capacity. Strong consortium of established partners including Northrop Grumman, Airbus, and Mitsubishi. Most publicly traded companies on team provide investor access.

Completed 28th milestone (CCDR) with NASA, transitioning to manufacturing phase, eligible for NASA milestone payments, and confirmed ISS-equivalent capabilities. Leading among the larger consortium teams.